Poly(ethyl ethylene phosphate) (PEEP) modified cellulose nanocrystals (CNCs) (CNC-g-PEEP) were synthesized through a “grafting onto” process, in which a combination of ring-opening polymerization (ROP) and Cu(I)-catalyzed azide–alkyne cycloaddition (CuAAC) “click” chemistry was utilized. The resulting suspension of negatively-charged CNC-g-PEEP nanocrystals could be used to encapsulate doxorubicin (DOX) by electrostatic interactions and release the drug in the tumor cell environment.

A new kind of reduction-cleavable polymer-camptothecin (CPT) prodrug has been developed, in which the polymer backbone consists of a biodegradable diblock polyphosphoester (PBYP-b-PEEP), and a modified CPT is linked onto the pendant alkynes of PBYP via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) “click” reaction to yield the polymeric prodrug, abbreviated as (PBYP-g-ss-CPT)-b-PEEP. The resulting prodrug could self-assemble into uniform prodrug micelles in aqueous solution. Since the releasable disulfide carbonate between the CPT and the polyphosphoester would be disrupted under an intracellular reducing environment, the disassociation of prodrug micelles could result in a rapid release of the CPT parent drug. The chemical structures of the intermediate polymers and a polymeric prodrug have been fully characterized by ¹H NMR and FT-IR analyses, while the molecular weights and molecular weight distributions were measured by gel permeation chromatography (GPC). The self-assembly behavior of the prodrug was investigated by the fluorescence probe method, dynamic light scattering (DLS) and transmission electron microscopy (TEM) analyses. The DLS results indicated that these prodrug micelles were relatively stable in neutral pH media, but could be degraded under the reductive conditions. The in vitro drug release studies showed that the CPT release from prodrug micelles was proceeded in a glutathione (GSH)-dependent manner. A methyl thiazolyl tetrazolium (MTT) assay demonstrated that the prodrug micelles could efficiently inhibit the proliferation of HepG2 cells. In addition, the intracellular uptake of prodrug micelles could efficiently release CPT into HepG2 cells, which was observed using a live cell imaging system. All these results indicated that this GSH-responsive polymeric prodrug has high potential for reduction-triggered cancer chemotherapy.

A series of acid-cleavable ABA-type triblock copolymers, namely poly(ε-caprolactone)-acetal-poly(ethylene glycol)-acetal-poly(ε-caprolactone) (PCL-a-PEG-a-PCL), were synthesized via a combination of ring-opening polymerization (ROP) of ε-caprolactone initiated by propargyl alcohol and subsequent “CuAAC” click reaction with azide terminated acetal-containing poly(ethylene glycol). The chemical composition and structures of the copolymers were characterized by ¹H NMR and FT-IR spectroscopy, while their molecular weights and molecular weight distributions were measured by gel permeation chromatography (GPC). The critical aggregation concentration (CAC), size parameters and morphologies of micelles self-assembled from PCL-a-PEG-a-PCL were determined by fluorescence probing, dynamic light scattering (DLS), and transmission electron microscopy (TEM), respectively. Since the acetal groups are unstable in weak acidic media, it is anticipated that this class of triblock copolymer micelles can be dissociated in an intracellular environment. This was confirmed by monitoring the size change of micelles with the increase of degradation time under acidic conditions, as well as the molecular weights of degradation products. The pH-triggered release of doxorubicin (DOX) from PCL-a-PEG-a-PCL micelles was studied and compared with a pH-insensitive PCL-b-PEG-b-PCL system without acetal groups, demonstrating that the cleavage of acetal linkages was responsible for the pH-responsive drug release profiles. In vitro cytotoxicity tests against HeLa and L929 cells by MTT assays indicated that the self-assembled micelles displayed very low cytotoxicity. In addition, the intracellular drug release against HeLa cells was further investigated by a live cell imaging system using free DOX as a control. This work provides a facile strategy for the preparation of a new type of biodegradable amphiphilic copolymer as a highly promising intracellular delivery system for hydrophobic drugs.

Multiple drugs in combinatory therapy can improve the treatment of cancer due to their efficient reduction of multidrug resistance (MDR) of tumor cells. In this paper, we first synthesized a reduction-sensitive dextran-ss-camptothecin (Dex-ss-CPT, or Dex-CPT) prodrug conjugated by a disulfide bond, and a pH-responsive dextran-hyd-doxorubicin (Dex-hyd-DOX, or Dex-DOX) prodrug linked with an acid-cleavable hydrazone group. The chemical structures of the intermediate polymers and polymeric prodrugs have been fully characterized by ¹H NMR, FT-IR, UV-Vis and HPLC analyses, respectively. Both prodrugs could self-assemble into uniform particles in aqueous solution. Subsequently, in vitro synergistic drug release of the two prodrugs was studied by methyl thiazolyl tetrazolium (MTT) assay. The reduction of a disulfide linker generates a thiol intermediate that is followed by intramolecular cyclization and the cleavage of the neighboring carbonate bridge, thus releasing native CPT molecules from the Dex-ss-CPT micelles. Similarly, the pH-sensitive hydrazone bond is broken under intracellular acidic conditions and the DOX parent drug is released from the Dex-hyd-DOX micelles. Finally, in vivo pharmacokinetics and biodistribution were investigated via intravenous administration with various formulations to treat 4T1 tumor-bearing mice. Meanwhile, the antitumor activity was also studied. This work demonstrates an effective anti-cancer prodrug design platform, which is expected to be useful for the treatment of various tumors.